Familial thrombophilia and retinal vein occlusion

Eye

Volumn 14, Issue 1, 2000, Pages 13-17

  Backhouse, O ^a,b   Parapia, L ^a   Mahomed, I ^a   Lee, D ^a  

^a BRADFORD ROYAL INFIRMARY   (United Kingdom)

^b Forge Cottage   (United Kingdom)

Author keywords

Factor V Leiden; Hyperhomocysteinaemia; Management; Prothrombin; Retinal vein occlusion; Thrombophilia; Thrombosis

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; FIBRINOGEN; HOMOCYSTEINE; LIPID; PROTHROMBIN;

ADULT; AGED; ARTICLE; BLOOD CELL COUNT; BLOOD RHEOLOGY; BLOOD VISCOSITY; DIABETES MELLITUS; DIAGNOSTIC TEST; FEMALE; GENE MUTATION; GLAUCOMA; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBESITY; RETINA VEIN OCCLUSION; RISK FACTOR; SMOKING; THROMBOPHILIA; VEIN THROMBOSIS;

EID: 0034097144     PISSN: 0950222X     EISSN: None     Source Type: Journal    
DOI: 10.1038/eye.2000.4     Document Type: Article

References (47)

1. The Eye Disease Case-Control Study Group. Risk factors for branch retinal vein occlusion. Am J Ophthalmol 1993;116:286-96.
2. The Eye Disease Case-Control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996;114:545-54.
3. The Eye Disease Case-Control Study Group. Risk factors for hemiretinal vein occlusion: comparison with risk factors for central and branch retinal vein occlusion. Ophthalmology 1998;105:765-71.
4. Rath EZ, Frank RN, Shin DH, et al. Risk factors for retinal vein occlusions: a case-control study. Ophthalmology 1992;99:509-14.
5. Appiah AP, Trempe CL. Risk factors associated with branch vs central retinal vein occlusion. Ann Ophthalmol 1989;21:153-7.
6. Glacet-Bernard A, Chabanel A, Lelong F, et al. Elevated erythrocyte aggregation in patients with CRVO with and without conventional risk factors. Ophthalmology 1994;101:1483-7.
7. Arend O, Remky A, Jung F, et al. Role of rheologic factors in patients with acute central retinal vein occlusion. Ophthalmology 1996;103:80-6.
8. Bandello F, Vigano D'Angelo S, Parlavecchia M, et al. Hypercoagulability and high lipoprotein (a) levels in patients with central retinal vein occlusion. Thromb Haemost 1994;72:39-43.
9. Larsson J, Olafsdottir E, Bauer B. Activated protein C resistance in young adults with central retinal vein occlusion. Br J Ophthalmol 1996;80:200-2.
10. Kumar B, Yu D, Morgan W, et al. The distribution of angioarchitectural changes within the vicinity of the arteriovenous crossing in branch retinal vein occlusion. Ophthalmology 1998;105:424-7.
11. Larsson J, Sellman A, Bauer B. Activated protein C resistance in patients with central retinal vein occlusion. Br J Ophthalmol 1997;81:832-4.
12. Zoller B, Svensson PJ, He X, et al. Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest 1994;94:2521-4.
13. Graham SL, Goldberg I, Murray B, et al. Activated protein C resistance: low incidence in glaucomatous optic disc haemorrhage and central retinal vein occlusion. Aust NZ J Ophthalmol 1996;24:199-205.
14. Hodgkins PR, Perry DJ, Sawcer SJ, et al. Factor V and antithrombin gene mutations in patients with idiopathic central retinal vein occlusion. Eye 1995;9:760-2.
15. Raguenes O, Mercier B, Escoffre M, et al. 1691 G to A mutation of the factor V gene: no association with thrombosis of the central retinal vein. Presse Med 1996;25:460.
16. Linna T, Ylikorkala A, Kontula K, et al. Prevalence of factor V Leiden in young adults with retinal vein occlusion. Thromb Haemost 1997;77:214-5.
17. Gottlieb JL, Blice JP, Mestichelli B. Activated protein C resistance, factor V Leiden and central retinal vein occlusion in young adults. Arch Ophthalmol 1998;116:577-9.
18. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
19. Bowen DJ, Bowley S, John M, et al. Factor V Leiden (G1691 A), the prothrombin 3′-untranslated region variant (G20210A) and thermolabile methylenetetrahydrofolate reductase (C677T): a single genetic test genotypes all three loci. Determination of frequencies in the S. Wales population of the UK. Thromb Haemost 1998;79:949-54.
20. Cox MJ, Rees DC, Martinson JJ, et al. Evidence for a single origin of factor V Leiden. Br J Haematol 1996;92:1022-5.
21. Rees DC, Cox M, Clegg JB. World distribution of factor V Leiden. Lancet 1995;346:1133-4.
22. Vandenbroucke JP, Koster T, Briet E, et al. Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7.
23. Baglin C, Brown K, Luddington R, et al. Risk of recurrent venous thromboembolism in patients with the factor V Leiden (FVR506Q) mutation: effect of warfarin and prediction by precipitating factors. Br J Haematol 1998;100:764-8.
24. Clark P, Brennand J, Conkie JA, et al. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998;79:1166-70.
25. Rosendaal FR, Doggen CJ, Zivelin A, et al. Geographic distribution of the 20210G to A prothrombin variant. Thromb Haemost 1998;79:706-8.
26. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
27. Hillarp A, Zoller B, Svensson PJ, et al. The 20210A allele of the prothrombin gene is a common risk factor among Swedish outpatients with verified deep venous thrombosis. Thromb Haemost 1997;78:990-2.
28. Longstreth WT, Rosendaal FR, Siscovick DS, et al. Risk of stroke in young women and two prothrombotic mutations: factor V Leiden and prothrombin gene variant (G20210A). Stroke 1998;29:577-80.
29. McCully KS. Homocysteine and vascular disease. Nature Med 1996;2:386-9.
30. Wenzler EM, Rademakers AJ, Boers GH, et al. Hyperhomocysteinaemia in retinal artery and retinal vein occlusion. Am J Ophthalmol 1993;115:162-7.
31. Biousse V, Newman NJ, Sternberg P. Retinal vein occlusion and transient monocular visual loss associated with hyperhomocystinemia. Am J Ophthalmol 1997;124:257-60.
32. Stein JH, McBride PE. Hyperhomocysteinemia and atherosclerotic vascular disease. Arch Intern Med 1998;158:1301-6.
33. Mayer EL, Jacobsen DW, Robinson K. Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996;27:517-27.
34. Rees MM, Rodgers GM. Homocysteinemia: association of a metabolic disorder with vascular disease and thrombosis. Thromb Res 1993;71:337-59.
35. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998;316:894-8.
36. Peterson JC, Spense JD. Vitamins and progression of atherosclerosis in hyperhomocysteinaemia. Lancet 1998;351:263.
37. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997;277:1775-81.
38. Still RA, McDowell IF. Clinical implications of plasma homocysteine measurements in cardiovascular disease. J Clin Pathol 1998;51:183-8.
39. Asherson RA, Khamashta MA, Ordi-Ros J, et al. The 'primary' antiphospholipid syndrome: major clinical and serological features. Medicine 1989;68:366-74.
40. Vila P, Hernandez MC, Lopez-Fernandez MF, et al. Prevalence, follow-up and clinical significance of the anticardolipin antibodies in normal subjects. Thromb Haemost 1994;72:209-13.
41. Rosove MH, Brewer PM. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992;117:303-8.
42. Boumpas DT, Fessier BJ, Austin HA, et al. Systemic lupus erythematosus: emerging concepts. 2. Dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality and pathogenesis. Ann Intern Med 1995;123:42-53.
43. Ames PR, Tommasino C, E'Andrea G, et al. Thrombophilic genotypes in subjects with idiopathic antiphospholipid antibodies: prevalence and significance. Thromb Haemost 1998;79:46-9.
44. Khamashta MA, Cuadrado MJ, Mujic F, et al. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995;332:993-7.
45. Guareschi G, Vigano D'Angelo S, Foresti V. Normal activities of protein C, protein S and antithrombin III in young patients with retinal vein occlusion. Haematologica 1990;75:483-4.
46. Chung MM, Trese MT, Hong YJ. Protein C levels in retinal vein occlusions. Invest Ophthalmol Vis Sci 1989;30:477.
47. Rosendaal FR. Thrombosis in the young: epidemiology and risk factors. A focus on venous thrombosis. Thromb Haemost 1997;78:1-6.